23andMe Investor Day Presentation Deck

CD200R1 was Identified as a Promising Anti-Cancer Drug Target with 23andMe's Proprietary Immuno-oncology (I/O) Genetic Signature Immune and autoimmune phenotypes Cancer phenotypes Identified novel immuno-oncology signature around CTLA4. tonsillectomy - t1d- anti_tnf_alpha_or_dmards - juvenile_t1d- iqb.dry_skin_frequency - iodine treatment ever- hypothyroidism - hyperthyroidism - hashimotos - graves - vitiligo- iqb.dandruff frequency - celiac HLA all- signed log(p) psoriasis- rheumatoid arthritis - took meds_anti_tnf_alpha- thyroid_removed - immunodeficiency - squamous_cell_carcinoma - basal cell carcinoma - actinic_keratosis - _non_melanoma_skin_cancer - any_skin_cancer - -10 -5 0 5 10 Genetic Variant in CTLA4 linked with multiple phenotypes in the 23andMe database CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature CD200R1 Receptor Immune I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes Cancer Cancer Immune CD200 Ligand DOK2 Protein Immune Cancer signed log(p) -10 -5 0 5 10 We discovered that 3 components of the signaling pathway for CD200R1 have a similar genetic signature to other I/O drugs Copyright © 2022 23andMe, Inc. 23andMeⓇ 35

View entire presentation